Overview
Investor fact sheet
News
Pipeline
Innovative Medicine pipeline
Development pipeline
Novel therapies
2024 Key events
Patent table
Financials
Quarterly results
Annual reports
SEC filings
Events & presentations
Stock info
Stock quote
Stock chart
Historical stock quote
Investment calculator
Dividend history
Stock split information
Governance
Corporate governance overview
2024 Annual Meeting of Shareholders
Board of Directors
Executive Committee
ESG resources
2023 Health for Humanity Report
2023 Janssen Transparency Report
Resources
Investor FAQs
Information request form
Investor email alerts
Investor contacts
Go to jnj.com
Skip to main content
Latest news
Our company
Careers
Investors
Media center
News Details
Overview
Investor fact sheet
News
Pipeline
Innovative Medicine pipeline
Development pipeline
Novel therapies
2024 Key events
Patent table
Financials
Quarterly results
Annual reports
SEC filings
Events & presentations
Stock info
Stock quote
Stock chart
Historical stock quote
Investment calculator
Dividend history
Stock split information
Governance
Corporate governance overview
2024 Annual Meeting of Shareholders
Board of Directors
Executive Committee
ESG resources
2023 Health for Humanity Report
2023 Janssen Transparency Report
Resources
Investor FAQs
Information request form
Investor email alerts
Investor contacts
Go to jnj.com
View all news
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
08/27/2024
Download
(opens in new window)
PDF
Multimedia Files:
View all news
Questions? Please contact us:
1-800-950-5089
investor-relations@its.jnj.com